{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T13:11:09Z","timestamp":1792501869832,"version":"4.5.0"},"reference-count":64,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2023,3,13]],"date-time":"2023-03-13T00:00:00Z","timestamp":1678665600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Dermatology"],"published-print":{"date-parts":[[2023,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Dupilumab, a monoclonal antibody inhibiting interleukin (IL) 4 and IL\u201013, is approved for the treatment of moderate to severe atopic dermatitis (AD) in children aged \u22656\u2009years, adolescents, and adults. Both clinical trials and real\u2010life data demonstrate its efficacy and safety. However, some cutaneous adverse events (cAEs) have been observed during real\u2010world experiences. The authors\u2019 aim was to analyze the spectrum of cAEs in patients receiving dupilumab for the treatment of AD in a real\u2010world setting. A retrospective review of electronic medical records was conducted for 916 patients (475 males and 541 females; mean age, 50.23\u2009\u00b1\u200919.66\u2009years [range, 18\u201391\u2009years]) who had received dupilumab for a minimum of 1\u00a0month for the treatment of AD from December 2018 to November 2022 at the Department of Dermatology of University Federico II of Naples (Italy). The mean duration of dupilumab treatment was 27.31\u2009\u00b1\u200921.26\u2009months. A total of 148 of 916 (16.15%) (90 males; mean age, 50.91\u2009\u00b1\u200915.34\u2009years) patients reported other cAEs apart of AD flare; namely, facial redness (82 of 916; 8.95%), psoriasis (39 of 916; 4.25%), alopecia areata (11 of 916; 1.2%), skin peeling (11 of 916; 1.2%), parapsoriasis (three of 916; 0.32%), and vitiligo (two of 916; 0.21%). Thirty\u2010one of 916 (3.38%) patients discontinued dupilumab because of cAEs (18 of 916; 1.96%) for facial redness, 10 of 916 (1.09%) for psoriasis, and three of 916 (0.32%) for parapsoriasis. In our population, most of the cAEs were mild and did not require discontinuation of dupilumab. These findings would enable dermatologists understand the cutaneous side effects of dupilumab better, resulting in improved treatment plan decisions in clinical practice.<\/jats:p>","DOI":"10.1111\/1346-8138.16764","type":"journal-article","created":{"date-parts":[[2023,3,14]],"date-time":"2023-03-14T00:54:06Z","timestamp":1678755246000},"page":"880-887","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Dupilumab\u2010associated cutaneous adverse events among adult patients with atopic dermatitis: A retrospective study"],"prefix":"10.1111","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3309-8190","authenticated-orcid":false,"given":"Maddalena","family":"Napolitano","sequence":"first","affiliation":[{"name":"Section of Dermatology, Department of Clinical Medicine and Surgery University of Naples Federico II  Naples Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0064-1874","authenticated-orcid":false,"given":"Gabriella","family":"Fabbrocini","sequence":"additional","affiliation":[{"name":"Section of Dermatology, Department of Clinical Medicine and Surgery University of Naples Federico II  Naples Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8661-2822","authenticated-orcid":false,"given":"Cataldo","family":"Patruno","sequence":"additional","affiliation":[{"name":"Department of Health Sciences University Magna Graecia of Catanzaro  Catanzaro Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,3,13]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1610020"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31191-1"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.16156"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.02.060"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)01539-2"},{"key":"e_1_2_8_7_1","first-page":"e384","article-title":"A 52\u2010week update of a multicentre Italian real\u2010world experience on effectiveness and safety of dupilumab in adolescents with moderate\u2010to\u2010severe atopic dermatitis [published online ahead of print, 2022 Oct 12]","volume":"37","author":"Stingeni L","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40272-022-00531-0"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2022.2102121"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.08.051"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2020.09.042"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.18176\/jiaci.0481"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-020-01379-9"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15059"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)30307-5"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.19330"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.5114\/ada.2022.117740"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xjidi.2021.100042"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.09.052"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2019.1612836"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.06.017"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.16348"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.01.012"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1097\/DER.0000000000000414"},{"key":"e_1_2_8_25_1","first-page":"265","article-title":"Dupilumab for allergic contact dermatitis: an overview of its use and impact on patch testing","volume":"109","author":"Johnson H","year":"2022","journal-title":"Cutis"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.05.013"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/dth.13142"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19459"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajd.13846"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1097\/DER.0000000000000740"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.17050"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2021.01.022"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-022-08934-0"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annder.2021.02.003"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.18176\/jiaci.0301"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2017.11.020"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1097\/DER.0000000000000458"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/ced.13858"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2018.10.010"},{"key":"e_1_2_8_40_1","article-title":"Dupilumab and alopecia: a Janus effect","volume":"5","author":"Patruno C","year":"2019","journal-title":"Dermatol Ther"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.1684\/ejd.2019.3626"},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2018.2976"},{"key":"e_1_2_8_43_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.16711"},{"key":"e_1_2_8_44_1","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1111\/ddg.13990","article-title":"Simultaneous effectiveness of dupilumab in atopic dermatitis and alopecia areata in two patients","volume":"17","author":"Ludriksone L","year":"2019","journal-title":"J Dtsch Dermatol Ges"},{"key":"e_1_2_8_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2018.11.006"},{"key":"e_1_2_8_46_1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-3183"},{"key":"e_1_2_8_47_1","doi-asserted-by":"publisher","DOI":"10.1002\/ccr3.2915"},{"key":"e_1_2_8_48_1","doi-asserted-by":"publisher","DOI":"10.1111\/dth.13582"},{"key":"e_1_2_8_49_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18976"},{"key":"e_1_2_8_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2020.10.010"},{"key":"e_1_2_8_51_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.15631"},{"key":"e_1_2_8_52_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22052618"},{"key":"e_1_2_8_53_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.15071"},{"key":"e_1_2_8_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.08.047"},{"key":"e_1_2_8_55_1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-3208"},{"key":"e_1_2_8_56_1","doi-asserted-by":"publisher","DOI":"10.12788\/cutis.0074"},{"key":"e_1_2_8_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.03.050"},{"key":"e_1_2_8_58_1","doi-asserted-by":"publisher","DOI":"10.1111\/dth.13880"},{"key":"e_1_2_8_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2015.02.1116"},{"key":"e_1_2_8_60_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2020.1948"},{"key":"e_1_2_8_61_1","doi-asserted-by":"publisher","DOI":"10.1159\/000182251"},{"key":"e_1_2_8_62_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.16388"},{"key":"e_1_2_8_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.03.051"},{"key":"e_1_2_8_64_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-07-590398"},{"key":"e_1_2_8_65_1","doi-asserted-by":"publisher","DOI":"10.2340\/actadv.v102.2234"}],"container-title":["The Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1346-8138.16764","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/1346-8138.16764","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1346-8138.16764","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,19]],"date-time":"2023-08-19T13:25:21Z","timestamp":1692451521000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1346-8138.16764"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,13]]},"references-count":64,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["10.1111\/1346-8138.16764"],"URL":"https:\/\/doi.org\/10.1111\/1346-8138.16764","archive":["Portico"],"relation":{},"ISSN":["0385-2407","1346-8138"],"issn-type":[{"value":"0385-2407","type":"print"},{"value":"1346-8138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,13]]},"assertion":[{"value":"2023-01-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-02-20","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-03-13","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}